# 9vhpv vaccine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/9vhpv-vaccine

> The next catalyst for 9vhpv vaccine, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, Jan to Apr 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | 9vhpv vaccine |
| Codes | V503 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Papillomavirus Infections](https://sec-api.dev/indications/papillomavirus-infections), [Genital Warts](https://sec-api.dev/indications/genital-warts) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Papillomavirus Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04199689 (Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04199689

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Papillomavirus Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04199689 (Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04199689

### Feb to May 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Genital Warts.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05314023 (Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05314023

### February 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Genital Warts.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05314023 (Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05314023

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Papillomavirus Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05285826 (Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-05-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05285826

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Papillomavirus Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05285826 (Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-05-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05285826

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Papillomavirus Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05450705 (V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-03 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05450705

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Papillomavirus Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05450705 (V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-03 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05450705

### Oct 2029 to Jan 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Papillomavirus Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04708041 (Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-23 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04708041

### October 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Papillomavirus Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04708041 (Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-23 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT04708041

## Same indication

- [V503](https://sec-api.dev/pdufa/v503) (MRK)

Calendar months: [January 2027](https://sec-api.dev/fda-calendar/2027-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/9vhpv-vaccine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "9vhpv vaccine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/9vhpv-vaccine

```bibtex
@misc{secapidev_pdufa_9vhpv_vaccine_20261116,
  title        = {9vhpv vaccine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/9vhpv-vaccine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_9vhpv_vaccine_20261116","title":"9vhpv vaccine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/9vhpv-vaccine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
